Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure

This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2004-05, Vol.93 (10), p.1309-1312
Hauptverfasser:	Parissis, John T, Adamopoulos, Stamatis, Antoniades, Charalambos, Kostakis, George, Rigas, Antonios, Kyrzopoulos, Stamos, Iliodromitis, Efstathios, Kremastinos, Dimitrios
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Adjuvants, Immunologic - therapeutic use Aged Cardiology Cardiotonic Agents - administration & dosage Cardiotonic Agents - pharmacology Cardiotonic Agents - therapeutic use Clinical trials Fas Ligand Protein Female Heart failure Heart Failure - blood Heart Failure - drug therapy Humans Hydrazones - administration & dosage Hydrazones - pharmacology Hydrazones - therapeutic use Infusions, Intravenous Interleukin-6 - blood Male Membrane Glycoproteins - blood Membrane Glycoproteins - drug effects Patients Placebo effect Pyridazines - administration & dosage Pyridazines - pharmacology Pyridazines - therapeutic use Ventricular Function, Left - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
ISSN:	0002-9149 1879-1913
DOI:	10.1016/j.amjcard.2004.01.073